Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs. More Details
Fair value with acceptable track record.
Share Price & News
How has Orient EuroPharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4120 is less volatile than 75% of TW stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 4120's weekly volatility (3%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: 4120 underperformed the TW Pharmaceuticals industry which returned 38.7% over the past year.
Return vs Market: 4120 underperformed the TW Market which returned 20.4% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Orient EuroPharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
20 hours ago | Simply Wall StAre Dividend Investors Getting More Than They Bargained For With Orient EuroPharma Co., Ltd.'s (GTSM:4120) Dividend?
3 weeks ago | Simply Wall StOrient EuroPharma's (GTSM:4120) Stock Price Has Reduced 28% In The Past Three Years
1 month ago | Simply Wall StWeak Financial Prospects Seem To Be Dragging Down Orient EuroPharma Co., Ltd. (GTSM:4120) Stock
Is Orient EuroPharma undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: 4120 (NT$50.3) is trading above our estimate of fair value (NT$40.92)
Significantly Below Fair Value: 4120 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 4120 is good value based on its PE Ratio (16.4x) compared to the TW Pharmaceuticals industry average (17.3x).
PE vs Market: 4120 is good value based on its PE Ratio (16.4x) compared to the TW market (18.6x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4120's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4120 is good value based on its PB Ratio (1.3x) compared to the TW Pharmaceuticals industry average (2.3x).
How is Orient EuroPharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Orient EuroPharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Orient EuroPharma is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Orient EuroPharma performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4120 has high quality earnings.
Growing Profit Margin: 4120's current net profit margins (4.7%) are higher than last year (3.9%).
Past Earnings Growth Analysis
Earnings Trend: 4120's earnings have declined by 5.8% per year over the past 5 years.
Accelerating Growth: 4120's earnings growth over the past year (14%) exceeds its 5-year average (-5.8% per year).
Earnings vs Industry: 4120 earnings growth over the past year (14%) underperformed the Pharmaceuticals industry 23.1%.
Return on Equity
High ROE: 4120's Return on Equity (4.4%) is considered low.
How is Orient EuroPharma's financial position?
Financial Position Analysis
Short Term Liabilities: 4120's short term assets (NT$4.3B) exceed its short term liabilities (NT$2.2B).
Long Term Liabilities: 4120's short term assets (NT$4.3B) exceed its long term liabilities (NT$1.8B).
Debt to Equity History and Analysis
Debt Level: 4120's debt to equity ratio (50.5%) is considered high.
Reducing Debt: 4120's debt to equity ratio has increased from 26.5% to 50.5% over the past 5 years.
Debt Coverage: 4120's debt is not well covered by operating cash flow (17.8%).
Interest Coverage: 4120's interest payments on its debt are well covered by EBIT (18x coverage).
What is Orient EuroPharma current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 4120's dividend (3.58%) is higher than the bottom 25% of dividend payers in the TW market (2.11%).
High Dividend: 4120's dividend (3.58%) is low compared to the top 25% of dividend payers in the TW market (5.17%).
Stability and Growth of Payments
Stable Dividend: 4120's dividend payments have been volatile in the past 10 years.
Growing Dividend: 4120's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonable payout ratio (58.7%), 4120's dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Mr. Peter Tsai has been the President and Chief Executive Officer of Orient Europharma Co., Ltd. Mr. Tsai serves as the Chairman of Orient Pharma Co., Ltd. and Orient Europharma Co. Ltd. Mr. Tsai studied f...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Orient EuroPharma Co., Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: Orient EuroPharma Co., Ltd.
- Ticker: 4120
- Exchange: GTSM
- Founded: 1982
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: NT$4.363b
- Shares outstanding: 86.75m
- Website: https://www.oepgroup.com/zh-TW
- Orient EuroPharma Co., Ltd.
- No. 368, Fu Hsing South Road
- 7th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4120||GTSM (Taipei Exchange)||Yes||Common Stock||TW||TWD||Nov 2003|
Orient EuroPharma Co., Ltd., a pharmaceutical company, develops and manufactures drugs. The company offers prescription medicines for cardiovascular, immunology, metabolism, neurology, gynecology, respirat...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/11/30 08:34|
|End of Day Share Price||2020/11/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.